Emerging data suggest that similar to peripheral nerve sheath tumors [32] and other primary brain tumors such as glioblastoma [33], PD-L1-induced immune-suppression may exert a biological role in the progression of meningioma to higher malignancy grade and possibly acts as a predictor of patient outcome. The gene discussed is CD274; the disease is meningioma.